COVID-19: Remdesivir, Hydroxychloroquine Data; Dietary Supplements Reviewed

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

Sun, May 31, 6:56 PM (16 hours ago)

to me

If you are having trouble viewing this email, click here.

TOP TRENDING Remdesivir Improves Time To Recovery for Patients Hospitalized With COVID-19 Hydroxychloroquine or Chloroquine for COVID-19: Large Study Finds No Benefit Evidence Supporting Dietary Supplement Use for COVID-19 Lacking Adenovirus Type 5 Vectored COVID-19 Vaccine Tolerable, Immunogenic in Phase 1 Study Merck Collaborating on Novel COVID-19 Vaccine, Oral Antiviral Phexxi, a Vaginal pH Regulator, Approved for Pregnancy Prevention Dupixent Approval Expanded to Pediatric Patients With Atopic Dermatitis Superpotent Lots of Hypothyroidism Treatment NP Thyroid Recalled Vesicare LS Approved for Neurogenic Detrusor Overactivity FDA Approval Expands Access of Artesunate for Malaria Treatment CME/CE Spotlight Dispelling the Myths of Influenza Management AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME